Wells Fargo analyst Larry Biegelsen has maintained their bullish stance on NVCR stock, giving a Buy rating yesterday. Larry Biegelsen has given his Buy rating due to a combination of
Wells Fargo analyst Larry Biegelsen has maintained their bullish stance on NVCR stock, giving a Buy rating yesterday. Larry Biegelsen has given his Buy rating due to a combination of
Piper Sandler analyst Jason Bednar raised the firm’s price target on Novocure to $28 from $25 and keeps an Overweight rating on the shares. The firm notes shares of Novocure
Novocur announced 20 presentations on Tumor Treating Fields therapy will be delivered at the American Association for Cancer Research, AACR, Annual Meeting 2024, to be held April 5 to 10
Wells Fargo lowered the firm’s price target on Novocure to $42 from $49 and keeps an Overweight rating on the shares. The firm says physician feedback points to METIS offering
החברה חושבת שרופאים רואים ב-METIS יתרון לחולים עם מטסטזות במוח, אך ייתכן שלא יגיע לכמות החולים כמו אלה עם גליובלסטומה (GBM). Wells Fargo מציינים כי האירועים החשובים הבאים להתבונן בהם